CROI 2017 Program and Information

Program and Agenda

565 OPTIMAL EFFICACY OF HCV-RESISTANCE–BASED RETREATMENTS AFTER PI FAILURE

Valeria Cento 1 , Silvia Barbaliscia 1 , Stefano Bonora 2 , Sergio Babudieri 3 , Alessia Ciancio 4 , Giuliano Rizzardini 5 , Mario Angelico 6 , Carlo F. Perno 1 , Francesca Ceccherini Silberstein 1 , for the Vironet Cohort 1 Univ of Rome Tor Vergata, Rome, Italy, 2 Univ degli Studi di Torino, Torino, Italy, 3 Univ of Sassari, Sassari, Italy, 4 City of Hlth and Sci of Turin, Turin, Italy, 5 Luigi Sacco Univ Hosp, Milano, Italy, 6 Hosp of Rome Tor Vergata, Rome, Italy 566 RETREATMENT OPTIONS AFTER FAILING A FIRST LINE OF DAAs AGAINST HEPATITIS C VIRUS 1 Complejo Hospario Univ de Granada, Granada, Spain, 2 Hosp General de Valencia, Valencia, Spain, 3 Hosp Univ Miguel Servet, Zaragoza, Spain, 4 Complejo Hospario Univ de Santiago, Santiago de Compostela, Spain, 5 Complejo Hospario Univ de Huelva, Huelva, Spain, 6 Hosp Regional Carlos Haya, Málaga, Spain, 7 Hosp Univ Virgen del Rocío, Sevilla, Spain, 8 Hosp Univ Reina Sofia, Cordoba, Spain 567 HCV REINFECTION AFTER SUCCESSFUL DAA TREATMENT: A GECCO ANALYSIS Patrick Ingiliz 1 , Stefan Christensen 2 , Florian Berger 3 , Torben Kimhofer 4 , Knud Schewe 5 , Christoph Boesecke 6 , Dietrich Hueppe 7 , Julian Schulze zur Wiesch 8 , Thomas Lutz 9 , Stefan Mauss 3 1 Cntr for Infectiology, Berlin, Germany, 2 CIM Infectious Diseases, Münster, Germany, 3 Cntr for HIV and Hepatogastroenterology, Duesseldorf, Germany, 4 Imperial Coll London, London, UK, 5 dagnae e.V., Berlin, Germany, 6 Univ Hosp Bonn, Bonn, Germany, 7 Gastroenterology Practice, Herne, Germany, 8 Univ Med Cntr, Hamburg-Eppendorf, Germany, Hamburg, Germany, 9 Infektiologikum, Frankfurt, Germany 568LB LEDIPASVIR/SOFOSBUVIR±RIBAVIRIN INHCV AND HCV/HIV PRIOR SOF-BASEDVIROLOGIC FAILURES Edward Tam 1 , Robert S. Brown, Jr 2 , Sanjaya Satapathy 3 , Gregory Camus 4 , Amanda Copans 4 , Lorenzo Rossaro 4 , Willliam D. Guyer 4 , Richard Haubrich 4 , Minhee Kang 5 , Annie Luetkemeyer 6 1 LAIR Cntr, Vancouver, Canada, 2 Weill Cornell Med, New York, NY, USA, 3 Univ of Tennessee, Memphis, TN, USA, 4 Gilead Scis, Inc, Foster City, CA, USA, 5 Harvard Univ, Boston, MA, USA, 6 Univ of California San Francisco, San Francisco, CA Ana B. Perez 1 , Natalia Chueca 1 , Miguel García-Deltoro 2 , Ana María Martínez- Sapiña 3 , Daniel Navarro 4 , Dolores Merino 5 , Miguel Jiménez 6 , Juan Manuel Pascasio 7 , Antonio Rivero 8 , Federico García 1 Poster P-L6 DAAs: TREATMENT AND ITS COMPLEXITIES Poster Hall - 4 EF 2:30 PM - 4:00 PM 569 NINETY-SIX%SVR RATES USING IMPORTED GENERIC DAAs FOR PATIENTSWITHHEPATITIS C Andrew Hill 1 , Giten Khwairakpam 2 , James Wang 3 , Sergey Golovin 4 , Julia Dragunova 5 , Rachel Smith 6 , Vicky Houghton-Price 6 , Roxanna S Korologou- Linden 7 , Anton Pozniak 8 , Greg Jefferys 9 1 St Stephens Cntr, Chelsea and Westminster Hosp, London, UK, 2 TREAT Asia/ amfAR, Bangkok, Thailand, 3 Ci Run Hlth Information Consulting Co Ltd, Kunming, China, 4 Intl Treatment Preparedness Coalition, St. Petersburg, Russian Federation, 5 Intl Treatment Preparedness Coalition and GEPATITKA Community, St. Petersburg, Russian Federation, 6 Metavirology Ltd, London, UK, 7 Imperial Coll London, London, UK, 8 Chelsea and Westminster NHS Fndn Trust, London, UK, 9 Univ of Tasmania, Tasmania, Australia

Poster Sessions • Wednesday

CROI 2017 141